ABSTRACT
INTRODUCTION
Cancer accounts for almost 15% of all deaths, worldwide, and has produced consistent death rates for over 50 years 1 . However, recent advances in immunotherapy generate anti-tumor, cytotoxic T cells (CTLs) that may dramatically impact patient outcomes 2, 3 . The T cell receptor complex (TCR) recognizes tumor-derived peptides bound to surface, major histocompatibility complexes (MHC) to produce specific and systemic tumor cell targeting. Cancer vaccine protocols load antigen presenting cells (APCs) with tumor-associated antigens and activate them to co-stimulate and expand anti-tumor, CTL immunity 3 . Clinically, vaccines have demonstrated the ability to augment T-cell reactions, and in 2010 the U.S. Food and Drug Administration approved the first, solid tumor vaccine, Provenge, for the treatment of advanced prostate cancer 3, 4 . Importantly, immunizations typically do not produce tumor shrinkage, which limits survival benefits 4 . This may be due, in part, to tumor-mediated signaling of CTLA-4 and PD-1, which dampens T-cell activity 2 . CTLA-4 suppresses T-cell activation by blocking T-cell costimulation during TCR ligation, whereas PD-1 engagement by PD-L1 and PD-L2 (expressed by tumor cells or co-opted resident cells) limits T-cell activity within tumors by promoting anergy, death, or exhaustion 2, 5, 6 . In addition, both CTLA-4 and PD-1 are expressed by T regulatory cells (Tregs), which may reside within tumors or lymphoid tissues to further suppress T cell activation 2, 6, 7 . This knowledge of tumor and T-cell biology is the basis for antibody therapies that specifically block these immunosuppressive checkpoints. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients 8, 9 . Antibodies targeting the PD-1 pathway have recently entered the clinic, and are showing dramatic effects in subsets of patients in a variety of cancer types 6 . Despite these successes, most treated subjects still succumb to progressive disease, indicating that vaccines or antibody therapies alone are insufficient to effect complete tumor cell killing 3, 4, 6, 9 .
Approaches that utilize therapeutic vaccines to produce CTLs, while inhibiting their suppression via checkpoint antibodies, should be synergistic in amplifying T-cell immunity and effecting tumor shrinkage. We recently developed a biomaterial-based, therapeutic vaccine that has unprecedented effectiveness in maintaining sustained T-cell responses and produces tumor regression in preclinical models of melanoma and other cancers 10, 11 . To test the effects of immune checkpoint blockade antibodies (anti-CTLA-4
and anti-PD-1) and cancer vaccines in combination, we utilized a therapeutic B16-F10 melanoma model. 10% fetal bovine serum (Life Technologies, Inc.), 100 units/ml penicillin, and 100 μg/ml streptomycin. The cells were maintained at 37°C in a humidified 5% CO 2 /95% air atmosphere and early passage cells (between 4 and 9) were utilized for experiments.
MATERIALS & METHODS
Mice. C57BL/6 mice (6-8-week-old female; Jackson Laboratories), were cared for in Statistical significance of differences between the groups were analyzed by a two-tailed, Student's t test and a P value of less than 0.05 was considered significant.
RESULTS
PLG matrices were fabricated, as described 10 , to coordinate the recruitment and anti-tumor programming of dendritic cells via the controlled presentation of tumor lysates with GM-CSF and CpG-rich ODN (PLG vaccines). In mice bearing 3-day-old B16 melanoma tumors (5x10 5 cells), treatment with CTLA-4 and PD-1 antibodies alone have no effect on tumor progression and survival outcomes in these animals ( Supplementary   Fig. S1 ). Moreover, a single PLG vaccination modestly suppressed tumor progression but did not effect long-term survival in any mice bearing B16 melanoma tumors (Fig. 1) .
Strikingly, treatment with CTLA-4 and PD-1 antibodies at day 3 combined with a single PLG vaccination at day 9 significantly reduced the rate of tumor progression and resulted in long-term survival rates of 75% and 40%, respectively, with complete tumor regression in the surviving mice (Fig. 1A-C 
Indeed, combining blockade antibodies with PLG vaccination significantly skewed the tumor infiltrating leukocyte (TIL) response toward active, cytotoxic T cells, relative to suppressive Tregs (Fig. 2 & S2) . This is consistent with the finding of tumor regression, as higher CD8/Treg ratios within tumors are indicative of effective vaccination 3, 9 . PLG vaccination at day 9 after tumor challenge induced significant Fig. 2A) . In contrast, these treatment groups had no effect on the numbers of tumor-resident CD4 were activated (Fig 2, D and E (Fig. 3B) . CTLA-4 blockade also enhanced T regulatory cell activity within vaccines relative to PD-1 combination or vaccination alone (Fig. 3C) . Importantly, the cytotoxic T cell to T reg ratio was approximately 3-fold greater with antibody addition in comparison to vaccine treatments alone (Fig. 3D) . In addition, increased CD8 
